Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Non Operating Income (2016 - 2025)

Seres Therapeutics' Non Operating Income history spans 11 years, with the latest figure at $2.8 million for Q3 2025.

  • For Q3 2025, Non Operating Income rose 111.67% year-over-year to $2.8 million; the TTM value through Sep 2025 reached $74.1 million, up 530.37%, while the annual FY2024 figure was -$14.1 million, 384.01% down from the prior year.
  • Non Operating Income for Q3 2025 was $2.8 million at Seres Therapeutics, down from $4.3 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $59.9 million in Q1 2025 and bottomed at -$24.3 million in Q3 2024.
  • The 5-year median for Non Operating Income is -$35000.0 (2021), against an average of $2.7 million.
  • The largest annual shift saw Non Operating Income plummeted 2457.14% in 2022 before it surged 11764.95% in 2025.
  • A 5-year view of Non Operating Income shows it stood at -$316000.0 in 2021, then tumbled by 404.75% to -$1.6 million in 2022, then skyrocketed by 424.08% to $5.2 million in 2023, then soared by 36.91% to $7.1 million in 2024, then tumbled by 59.86% to $2.8 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Non Operating Income are $2.8 million (Q3 2025), $4.3 million (Q2 2025), and $59.9 million (Q1 2025).